Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
Respiratory syncytial virus prophylaxis in cystic...
Journal article

Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005–2016)

Abstract

Respiratory syncytial virus (RSV) may cause severe illness in cystic fibrosis (CF) children, but recommendations vary on prophylaxis. CARESS is a prospective registry of children who received palivizumab in 32 Canadian sites from 2005 to 2016. Demographic data were collected at enrollment and respiratory illness-related events recorded monthly. We reviewed respiratory illness hospitalization (RIH) and RSV hospitalization (RSVH) in CF children …

Authors

Mitchell I; Wong SK; Paes B; Ruff M; Bjornson C; Li A; Lanctôt KL; the CARESS investigators

Journal

European Journal of Clinical Microbiology & Infectious Diseases, Vol. 37, No. 7, pp. 1345–1352

Publisher

Springer Nature

Publication Date

July 2018

DOI

10.1007/s10096-018-3256-0

ISSN

0934-9723